Retracted: MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway

Abstract

Cancer Biotherapy and Radiopharmaceuticals

officially retracts the paper entitled, “MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway,” by Hong Dai, Chunmei Wang, Zhihai Yu, Donglin He, Kun Yu, Yin Liu, and Sheng Wang (Cancer Biother Radiopharm 2018;33(3):103–109. doi: 10.1089/cbr.2017.2386) due to the authors' admission that the paper was submitted by a paper mill. A message from the corresponding author reads as follows:

“I'm very sorry to tell you that some of the experiments in this paper were delegated to an outsourced laboratories inc. because the experimental conditions are limited in our affiliation. The terrible thing is that the laboratories inc. has been found out experimental misconduct. Unfortunately, our paper is involved in. We have to apply for withdrawal of this paper, which is also under investigation of our affiliation.

[sic]”

The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves and does not tolerate any violations of scientific misconduct.